Six readers
| reader | found | score |
|---|---|---|
| genetics Open Targets | no genetic evidence; overall 0.01 from other evidence | 0.00 |
| cell type Human Protein Atlas | cell type enhanced, including brain excitatory neurons; strongest in adipocytes | 0.75 |
| chemistry Open Targets | reachable by antibody | 0.36 |
| trials ClinicalTrials.gov | no Parkinson's trials on record: an open field | 1.00 |
| literature PubMed | 2 Parkinson's papers of 64 | 0.85 |
| pathways Reactome | in no curated pathway | 0.00 |
No case: the score is under the bar. Receipt 11049
Sealed predictions
- CLSTN2 in dopamine neurons, braak-0.36 (p 0.347) → +0.55 (p 0.128)receipt 11055
Swarm cases
receipt 11055: CLSTN2 in dopamine neurons, braak
- power
- full sample +0.02 (p 0.942, n 18), 95% CI -0.45 to +0.48. the interval is wide: not enough donors to tell.
- confounder
- adjusted for sex: -0.01 (p 0.962, n 18). does not hold up.
- composition
- dopamine neurons share of nuclei vs axis +0.05 (p 0.854); controlling for it: -0.47 (p 0.049, n 18). could be the mix.
- skeptic
- leave-one-out range -0.10 to +0.15, sign flips 7; without severely affected donors +0.02 (p 0.942, n 18). fragile.
- cell type
- no other cell group does better.
- axis
- no measure beats "tracks Braak Lewy-body stage" for CLSTN2 in dopamine neurons.
case closed: nothing better to follow up.
Receipts
loading the receipts